Trial · NCT00273754
The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).
NCT00273754, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2010-11-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA). Trials, record NCT00273754. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00273754
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).
- NCT number
- NCT00273754
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 74 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Sleep Apnea, Obstructive, Tonsillectomy, Adenoidectomy, Postoperative Complications
- Interventions
- Caffeine, Placebo
- First posted
- 2006-01-09
- Last updated
- 2016-06-16
- Results first posted
- 2010-11-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. | The number of children having adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation \<95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the Operating Room and in the PACU was recorded. |
| Secondary | Occurence of Post Extubatory Respiratory Adverse Events. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. | The overall occurance of adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation \<95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the OR and in the PACU was noted. |
| Secondary | Extubation Time. | Duration from anesthesia end until extubation time. | Time from end of anesthesia until extubation. |
| Secondary | Awakening Time | Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score. | A child with a Steward Recovery Scale score of 6 is defined as awake, coughing/crying, and has purposeful movements. |
| Secondary | Post Anesthesia Care Unit (PACU) Duration | Time spent in PACU following surgical procedure prior to discharge home or hospital admission. | |
| Secondary | Hospital Discharge Time | Total time from end anesthesia to discharge home | Children were discharged from the hospital when they reached the hospital discharge criteria: they were awake, had stable vital signs, were breathing adequately, had O2 saturation \>95% while breathing room air, were able to swallow fluids, had no or minimal pain, and were able to ambulate without excessive nausea, vomiting, or dizziness. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. | The analysis was per protocol. | Participants | NUMBER |
| SECONDARY | Occurence of Post Extubatory Respiratory Adverse Events. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. | Per protocol | Participants | NUMBER |
| SECONDARY | Extubation Time. | Duration from anesthesia end until extubation time. | minutes | MEAN | |
| SECONDARY | Awakening Time | Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score. | Minutes | MEAN | |
| SECONDARY | Post Anesthesia Care Unit (PACU) Duration | Time spent in PACU following surgical procedure prior to discharge home or hospital admission. | minutes | MEAN | |
| SECONDARY | Hospital Discharge Time | Total time from end anesthesia to discharge home | Minutes | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | Placebo | 21 | Participants | ||
| Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | Caffeine | 11 | Participants | ||
| Occurence of Post Extubatory Respiratory Adverse Events. | Placebo | 34 | Participants | ||
| Occurence of Post Extubatory Respiratory Adverse Events. | Caffeine | 17 | Participants | ||
| Extubation Time. | Placebo | 11.3 | Standard Deviation 9.4 | minutes | |
| Extubation Time. | Caffeine | 8.6 | Standard Deviation 4.9 | minutes | |
| Awakening Time | Placebo | 26.6 | Standard Deviation 16.0 | Minutes | |
| Awakening Time | Caffeine | 26.1 | Standard Deviation 28.8 | Minutes | |
| Post Anesthesia Care Unit (PACU) Duration | Placebo | 74.4 | Standard Deviation 43.7 | minutes | |
| Post Anesthesia Care Unit (PACU) Duration | Caffeine | 84.8 | Standard Deviation 44.1 | minutes |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 36 | |
| Overall Study | STARTED | Caffeine | 36 | |
| Overall Study | COMPLETED | Placebo | 36 | |
| Overall Study | COMPLETED | Caffeine | 36 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Caffeine | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Caffeine | ||
| Total, other adverse events | Placebo | 0 | 36 |
| Total, other adverse events | Caffeine | 0 | 36 |
| Total, serious adverse events | Placebo | 0 | 36 |
| Total, serious adverse events | Caffeine | 0 | 36 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Caffeine vs Placebo: Occurence of Post Extubatory Respiratory Adverse Events. | Trial comparisons |
| Caffeine vs Placebo: Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | Trial comparisons |
| Caffeine vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00273754
GET https://conductscience.org/api/trials/v1/NCT00273754/registered